Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing small molecule inhibitors to target resistance mechanisms in hematologic and solid malignancies, has acquired Ness Therapeutics Inc in an all-equity transaction.   Ness is developing PTPN2 inhibitors, providing an immuno-oncological therapy with an improved safety and tolerability profile.   Protein tyrosine phosphatase non-receptor type 2 (PTPN2), also known as T cell protein tyrosine phosphatase (T...